Alkermes (ALKS) Non Operating Income (2010 - 2026)
Alkermes (ALKS) posted quarterly Non Operating Income of -$20.2 million for Q2 2026, down 270.55% year-over-year from $11.9 million in Q2 2025, and down 48.24% quarter-over-quarter from -$13.6 million in Q1 2026.
Alkermes (ALKS) Non Operating Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Non Operating Income for 17 consecutive years, with -$20.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non Operating Income fell 270.55% year-over-year to -$20.2 million; the TTM figure through Jun 2026 stood at -$19.9 million (down 155.03% YoY), while the FY2025 annual figure was $37.5 million, up 62.21% from the prior year.
- Non Operating Income fell to -$20.2 million in Q2 2026 per ALKS's latest filing, from -$13.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $11.9 million in Q2 2025 and bottomed at -$20.2 million in Q2 2026.
- Historically, Non Operating Income has averaged $505055.6 across 5 years, with a median of $2.9 million in 2023.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 729.04% — and 2024, when it soared 1120.71%.
- Alkermes' Non Operating Income stood at -$1.1 million in 2022, then surged by 433.18% to $3.7 million in 2023, then jumped by 95.41% to $7.2 million in 2024, then sank by 68.43% to $2.3 million in 2025, then plunged by 989.97% to -$20.2 million in 2026.
- Business Quant data shows ALKS's Non Operating Income at -$20.2 million in Q2 2026, -$13.6 million in Q1 2026, and $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | -20.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.23 Mn |
| Mar 31, 2026 | -13.65 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | 11.66 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 11.70 Mn |
| Dec 31, 2024 | 7.20 Mn |
| Sep 30, 2024 | 5.47 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Mar 31, 2024 | 3.60 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Sep 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 560,000.00 |
| Mar 31, 2023 | -361,000.00 |
| Dec 31, 2022 | -1.11 Mn |
| Sep 30, 2022 | -6.73 Mn |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | -18.41 Mn |
| Dec 31, 2021 | -2.16 Mn |
| Sep 30, 2021 | -6.88 Mn |